A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease

Elizabeth N. Da Silva, Alan Baker, Jalila Al-Shekaili, Krishna Karpe, Matthew C. Cook

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Chronic kidney disease (CKD) is associated with an increased risk of hepatitis B infection and impaired seroconversion to hepatitis B vaccine (HBV). Studies examining augmented vaccine schedules to enhance seroconversion have so far been inconclusive. Furthermore, the defects responsible for impaired vaccine immunity in CKD have not yet been identified. Methods We studied serological and cellular responses to HBV in CKD to identify a defect in vaccineinduced cellular responses that could account for impaired seroconversion in CKD and clarify the effects of an augmented vaccine dose schedule. We compared these results with responses to seasonal influenza vaccination (Fluvax). Results We found a clear benefit in rates and magnitude of seroconversion after an augmented 40mcg HBV dose schedule in CKD. This permitted comparison of responders and nonresponders. Serological non-responders with CKD exhibited reduction in CXCR3+CCR6- CXCR5+ memory T cells at baseline. Unlike Fluvax, HBV elicited a poor plasmablast (PB) response. Both vaccinations induced activation of the CXCR3+CCR6- CCR7- subset of circulating T follicular helper cells (cTFH), although this response was impaired in CKD after HBV. Conclusions CKD confers a specific T cell defect that contributes to the impaired seroconversion to HBV.

Original languageEnglish
Article numbere0204477
JournalPLoS One
Volume13
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

hepatitis B
kidney diseases
Hepatitis B
Chronic Renal Insufficiency
Hepatitis B Vaccines
Vaccination
vaccination
vaccines
seroconversion
Appointments and Schedules
Vaccines
T-cells
Defects
T-lymphocytes
T-Lymphocytes
Helper-Inducer T-Lymphocytes
Human Influenza
dosage
Immunity
influenza

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease. / Da Silva, Elizabeth N.; Baker, Alan; Al-Shekaili, Jalila; Karpe, Krishna; Cook, Matthew C.

In: PLoS One, Vol. 13, No. 10, e0204477, 01.10.2018.

Research output: Contribution to journalArticle

Da Silva, Elizabeth N. ; Baker, Alan ; Al-Shekaili, Jalila ; Karpe, Krishna ; Cook, Matthew C. / A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease. In: PLoS One. 2018 ; Vol. 13, No. 10.
@article{7e11195853a34979bef11def67e7e924,
title = "A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease",
abstract = "Background Chronic kidney disease (CKD) is associated with an increased risk of hepatitis B infection and impaired seroconversion to hepatitis B vaccine (HBV). Studies examining augmented vaccine schedules to enhance seroconversion have so far been inconclusive. Furthermore, the defects responsible for impaired vaccine immunity in CKD have not yet been identified. Methods We studied serological and cellular responses to HBV in CKD to identify a defect in vaccineinduced cellular responses that could account for impaired seroconversion in CKD and clarify the effects of an augmented vaccine dose schedule. We compared these results with responses to seasonal influenza vaccination (Fluvax). Results We found a clear benefit in rates and magnitude of seroconversion after an augmented 40mcg HBV dose schedule in CKD. This permitted comparison of responders and nonresponders. Serological non-responders with CKD exhibited reduction in CXCR3+CCR6- CXCR5+ memory T cells at baseline. Unlike Fluvax, HBV elicited a poor plasmablast (PB) response. Both vaccinations induced activation of the CXCR3+CCR6- CCR7- subset of circulating T follicular helper cells (cTFH), although this response was impaired in CKD after HBV. Conclusions CKD confers a specific T cell defect that contributes to the impaired seroconversion to HBV.",
author = "{Da Silva}, {Elizabeth N.} and Alan Baker and Jalila Al-Shekaili and Krishna Karpe and Cook, {Matthew C.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1371/journal.pone.0204477",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease

AU - Da Silva, Elizabeth N.

AU - Baker, Alan

AU - Al-Shekaili, Jalila

AU - Karpe, Krishna

AU - Cook, Matthew C.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background Chronic kidney disease (CKD) is associated with an increased risk of hepatitis B infection and impaired seroconversion to hepatitis B vaccine (HBV). Studies examining augmented vaccine schedules to enhance seroconversion have so far been inconclusive. Furthermore, the defects responsible for impaired vaccine immunity in CKD have not yet been identified. Methods We studied serological and cellular responses to HBV in CKD to identify a defect in vaccineinduced cellular responses that could account for impaired seroconversion in CKD and clarify the effects of an augmented vaccine dose schedule. We compared these results with responses to seasonal influenza vaccination (Fluvax). Results We found a clear benefit in rates and magnitude of seroconversion after an augmented 40mcg HBV dose schedule in CKD. This permitted comparison of responders and nonresponders. Serological non-responders with CKD exhibited reduction in CXCR3+CCR6- CXCR5+ memory T cells at baseline. Unlike Fluvax, HBV elicited a poor plasmablast (PB) response. Both vaccinations induced activation of the CXCR3+CCR6- CCR7- subset of circulating T follicular helper cells (cTFH), although this response was impaired in CKD after HBV. Conclusions CKD confers a specific T cell defect that contributes to the impaired seroconversion to HBV.

AB - Background Chronic kidney disease (CKD) is associated with an increased risk of hepatitis B infection and impaired seroconversion to hepatitis B vaccine (HBV). Studies examining augmented vaccine schedules to enhance seroconversion have so far been inconclusive. Furthermore, the defects responsible for impaired vaccine immunity in CKD have not yet been identified. Methods We studied serological and cellular responses to HBV in CKD to identify a defect in vaccineinduced cellular responses that could account for impaired seroconversion in CKD and clarify the effects of an augmented vaccine dose schedule. We compared these results with responses to seasonal influenza vaccination (Fluvax). Results We found a clear benefit in rates and magnitude of seroconversion after an augmented 40mcg HBV dose schedule in CKD. This permitted comparison of responders and nonresponders. Serological non-responders with CKD exhibited reduction in CXCR3+CCR6- CXCR5+ memory T cells at baseline. Unlike Fluvax, HBV elicited a poor plasmablast (PB) response. Both vaccinations induced activation of the CXCR3+CCR6- CCR7- subset of circulating T follicular helper cells (cTFH), although this response was impaired in CKD after HBV. Conclusions CKD confers a specific T cell defect that contributes to the impaired seroconversion to HBV.

UR - http://www.scopus.com/inward/record.url?scp=85054771997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054771997&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0204477

DO - 10.1371/journal.pone.0204477

M3 - Article

C2 - 30303980

AN - SCOPUS:85054771997

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0204477

ER -